Literature DB >> 23205959

How theories evolved concerning the mechanism of action of barbiturates.

Wolfgang Löscher1, Michael A Rogawski.   

Abstract

The barbiturate phenobarbital has been in use in the treatment of epilepsy for 100 years. It has long been recognized that barbiturates act by prolonging and potentiating the action of γ-aminobutyric acid (GABA) on GABA(A) receptors and at higher concentrations directly activating the receptors. A large body of data supports the concept that GABA(A) receptors are the primary central nervous system target for barbiturates, including the finding that transgenic mice with a point mutation in the β3 GABA(A) -receptor subunit exhibit diminished sensitivity to the sedative and immobilizing actions of the anesthetic barbiturate pentobarbital. Although phenobarbital is only modestly less potent as a GABA(A) -receptor modulator than pentobarbital, phenobarbital is minimally sedating at effective anticonvulsant doses. Possible explanations for the reduced sedative effect of phenobarbital include more regionally restricted action; partial agonist activity; reduced propensity to directly activate GABA(A) receptors (possibly including extrasynaptic receptors containing δ subunits); and reduced activity at other ion channel targets, including voltage-gated calcium channels. In recent years, substantial progress has been made in defining the structural features of GABA(A) receptors responsible for gating and allosteric modulation by drugs. Although the precise sites of action of barbiturates have not yet been defined, the second and third transmembrane domains of the β subunit appear to be critical; binding may involve a pocket formed by β-subunit methionine 286 as well as α-subunit methionine 236. In addition to effects on GABA(A) receptors, barbiturates block AMPA/kainate receptors, and they inhibit glutamate release through an effect on P/Q-type high-voltage activated calcium channels. The combination of these various actions likely accounts for their diverse clinical activities. Despite the remarkable progress of the last century, there is still much to learn about the actions of barbiturates that can be applied to the discovery of new, more therapeutically useful agents. Wiley Periodicals, Inc.
© 2012 International League Against Epilepsy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23205959     DOI: 10.1111/epi.12025

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  40 in total

1.  Identifying barbiturate binding sites in a nicotinic acetylcholine receptor with [3H]allyl m-trifluoromethyldiazirine mephobarbital, a photoreactive barbiturate.

Authors:  Ayman K Hamouda; Deirdre S Stewart; David C Chiara; Pavel Y Savechenkov; Karol S Bruzik; Jonathan B Cohen
Journal:  Mol Pharmacol       Date:  2014-02-21       Impact factor: 4.436

2.  Rapid Throughput Analysis of GABAA Receptor Subtype Modulators and Blockers Using DiSBAC1(3) Membrane Potential Red Dye.

Authors:  Atefeh Mousavi Nik; Brandon Pressly; Vikrant Singh; Shane Antrobus; Susan Hulsizer; Michael A Rogawski; Heike Wulff; Isaac N Pessah
Journal:  Mol Pharmacol       Date:  2017-04-20       Impact factor: 4.436

3.  Treatment of Convulsive Status Epilepticus.

Authors:  Eric H Grover; Yara Nazzal; Lawrence J Hirsch
Journal:  Curr Treat Options Neurol       Date:  2016-03       Impact factor: 3.598

4.  Structural and functional studies of the modulator NS9283 reveal agonist-like mechanism of action at α4β2 nicotinic acetylcholine receptors.

Authors:  Jeppe A Olsen; Philip K Ahring; Jette S Kastrup; Michael Gajhede; Thomas Balle
Journal:  J Biol Chem       Date:  2014-06-30       Impact factor: 5.157

5.  Knockout of alpha 5 nicotinic acetylcholine receptors subunit alters ethanol-mediated behavioral effects and reward in mice.

Authors:  Anton Dawson; Jennifer T Wolstenholme; Monzurul A Roni; Vera C Campbell; Asti Jackson; Cassandra Slater; Deniz Bagdas; Erika E Perez; Jill C Bettinger; Mariella De Biasi; Michael F Miles; M Imad Damaj
Journal:  Neuropharmacology       Date:  2018-06-23       Impact factor: 5.250

6.  TrkB agonists prevent postischemic emergence of refractory neonatal seizures in mice.

Authors:  Pavel A Kipnis; Brennan J Sullivan; Brandon M Carter; Shilpa D Kadam
Journal:  JCI Insight       Date:  2020-06-18

Review 7.  The pharmacology of imepitoin: the first partial benzodiazepine receptor agonist developed for the treatment of epilepsy.

Authors:  Chris Rundfeldt; Wolfgang Löscher
Journal:  CNS Drugs       Date:  2014-01       Impact factor: 5.749

8.  Barbiturates Bind in the GLIC Ion Channel Pore and Cause Inhibition by Stabilizing a Closed State.

Authors:  Zaineb Fourati; Reinis Reinholds Ruza; Duncan Laverty; Emmanuelle Drège; Sandrine Delarue-Cochin; Delphine Joseph; Patrice Koehl; Trevor Smart; Marc Delarue
Journal:  J Biol Chem       Date:  2016-12-16       Impact factor: 5.157

9.  Location of the Mesopontine Neurons Responsible for Maintenance of Anesthetic Loss of Consciousness.

Authors:  Anne Minert; Shai-Lee Yatziv; Marshall Devor
Journal:  J Neurosci       Date:  2017-08-16       Impact factor: 6.167

10.  The use of antiviral drugs for influenza: Guidance for practitioners 2012/2013.

Authors:  Fred Y Aoki; Upton D Allen; H Grant Stiver; Gerald A Evans
Journal:  Can J Infect Dis Med Microbiol       Date:  2012       Impact factor: 2.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.